ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
1.50%
Brent Oil
83.76
0.00%
Bitcoin
66,986.49
-0.14%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) News

Hutchmed (china) (HCM)

Hutchmed (china) Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:HCM
DateTimeSourceHeadlineSymbolCompany
17/05/202417:58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
17/05/202415:00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
17/05/202407:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
14/05/202414:33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
14/05/202407:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
14/05/202407:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
10/05/202413:00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
08/05/202409:30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
26/04/202416:09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
26/04/202413:30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
22/04/202409:30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
08/04/202409:30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
05/04/202409:30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
02/04/202410:32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
02/04/202407:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
28/03/202411:08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
28/03/202407:00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
22/03/202410:09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
22/03/202407:16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
22/03/202407:00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
14/03/202409:00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
05/03/202408:30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
28/02/202417:31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
28/02/202412:45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
28/02/202411:30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
07/02/202409:50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
07/02/202407:00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
02/02/202409:52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
02/02/202408:37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
01/02/202408:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Your Recent History

BIT
A2A
A2A
BIT
S29099
Societe Generale Effekten
LSE
FSG
Foresight
BIT
Q00251
Leonteq Securities
LSE
3APE
Ls 3x Apple
BIT
T00007
Banca Cesare Ponti
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved